- Home
- SST vs NRSN Comparison
SST vs NRSN Comparison
Compare SST & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SST
- NRSN
- Stock Information
- Founded
- SST 2013
- NRSN 2017
- Country
- SST United States
- NRSN Israel
- Employees
- SST N/A
- NRSN N/A
- Industry
- SST Diversified Commercial Services
- NRSN Biotechnology: Pharmaceutical Preparations
- Sector
- SST Consumer Discretionary
- NRSN Health Care
- Exchange
- SST Nasdaq
- NRSN Nasdaq
- Market Cap
- SST 23.3M
- NRSN 26.0M
- IPO Year
- SST N/A
- NRSN 2021
- Fundamental
- Price
- SST $0.44
- NRSN $1.04
- Analyst Decision
- SST Strong Buy
- NRSN Hold
- Analyst Count
- SST 1
- NRSN 1
- Target Price
- SST $5.00
- NRSN N/A
- AVG Volume (30 Days)
- SST 136.3K
- NRSN 99.3K
- Earning Date
- SST 05-06-2025
- NRSN 06-23-2025
- Dividend Yield
- SST N/A
- NRSN N/A
- EPS Growth
- SST N/A
- NRSN N/A
- EPS
- SST N/A
- NRSN N/A
- Revenue
- SST $333,521,000.00
- NRSN N/A
- Revenue This Year
- SST N/A
- NRSN N/A
- Revenue Next Year
- SST $8.34
- NRSN N/A
- P/E Ratio
- SST N/A
- NRSN N/A
- Revenue Growth
- SST N/A
- NRSN N/A
- 52 Week Low
- SST $0.29
- NRSN $0.51
- 52 Week High
- SST $1.94
- NRSN $1.50
- Technical
- Relative Strength Index (RSI)
- SST 53.76
- NRSN 53.20
- Support Level
- SST $0.37
- NRSN $0.93
- Resistance Level
- SST $0.53
- NRSN $1.08
- Average True Range (ATR)
- SST 0.08
- NRSN 0.06
- MACD
- SST 0.01
- NRSN 0.01
- Stochastic Oscillator
- SST 50.36
- NRSN 71.12
About SST System1 Inc.
System1 Inc develops technology and data science to operate a responsive acquisition marketing platform. It serves customers in the areas of health and wellness, automotive, finance, travel, and entertainment. The company's segment includes Owned and Operated Advertising (O&O); and Partner Network. It generates maximum revenue from the Owned and Operated Advertising (O&O) segment. Geographically, it operates in United States and Other countries.
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, these diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.